Kaoru Ando, Tetsu Watanabe, Yamagata Univ Sch of Med, Yamagata, Japan; Hyuma Daidoji, Yamagata Prefectural Central Hosp, Yamagata, Japan; Yoichiro Otaki, Naoto Hashimoto, Yu Kumagai, Naoaki Hashimoto, Taro Narumi, Shinpei Kadowaki, Gensai Yamaura, Masahiro Wanezaki, Akira Funayama, Yoshinori Yashiro, Tadateru Iwayama, Satoshi Nishiyama, Hiroki Takahashi, Takanori Arimoto, Tetsuro Shishido, Takuya Miyamoto, Isao Kubota, Yamagata Univ Sch of Med, Yamagata, Japan
K. Ando: None. T. Watanabe: None. H. Daidoji: None. Y. Otaki: None. N. Hashimoto: None. Y. Kumagai: None. N. Hashimoto: None. T. Narumi: None. S. Kadowaki: None. G. Yamaura: None. M. Wanezaki: None. A. Funayama: None. Y. Yashiro: None. T. Iwayama: None. S. Nishiyama: None. H. Takahashi: None. T. Arimoto: None. T. Shishido: None. T. Miyamoto: None. I. Kubota: None.
High intensity statin therapy is established for secondary prevention of coronary heart disease (CHD). However, additional therapy is required to reduce residual risk in CHD patients with aggressive lipid-lowering therapy. Eicosapentaenoic acid (EPA) was reported to be beneficial especially in secondary prevention. The aim of this study was to investigate whether coronary plaque regression and stabilization are reinforced by additional administration of EPA to high dose pitavastatin (PTV) therapy.
We enrolled 200 CHD patients who underwent percutaneous coronary intervention in 6 hospitals. Patients were randomly allocated to PTV group (PTV 4 mg/day, n=98) and PTV/EPA group (PTV 4 mg/day and EPA 1800 mg/day, n=102), and prospectively followed for 6 to 8 months. Coronary plaque volume and composition in non-stenting lesion were analyzed by integrated backscatter intravascular ultrasonography at baseline and follow up.